## Tyler E Jacks

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/375982/publications.pdf

Version: 2024-02-01

114 papers 45,006 citations

75 h-index 26792 111 g-index

125 all docs

 $\begin{array}{c} 125 \\ \text{docs citations} \end{array}$ 

125 times ranked

51899 citing authors

#	Article	IF	CITATIONS
1	p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature, 1993, 362, 847-849.	13.7	2,829
2	Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature, 2009, 462, 108-112.	13.7	2,707
3	Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature, 1996, 379, 88-91.	13.7	2,223
4	Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell, 2003, 4, 437-450.	7.7	2,150
5	Tumor spectrum analysis in p53-mutant mice. Current Biology, 1994, 4, 1-7.	1.8	1,903
6	Effects of an Rb mutation in the mouse. Nature, 1992, 359, 295-300.	13.7	1,730
7	Sunburn and p53 in the onset of skin cancer. Nature, 1994, 372, 773-776.	13.7	1,724
8	Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes and Development, 2001, 15, 3243-3248.	2.7	1,663
9	Restoration of p53 function leads to tumour regression in vivo. Nature, 2007, 445, 661-665.	13.7	1,662
10	Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature, 1995, 377, 552-557.	13.7	1,218
11	Mutant p53 Gain of Function in Two Mouse Models of Li-Fraumeni Syndrome. Cell, 2004, 119, 847-860.	13.5	1,140
12	Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature, 2001, 410, 1111-1116.	13.7	1,060
13	Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. Nature Biotechnology, 2014, 32, 551-553.	9.4	823
14	Tumour predisposition in mice heterozygous for a targeted mutation in Nf1. Nature Genetics, 1994, 7, 353-361.	9.4	731
15	Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase. Nature Protocols, 2009, 4, 1064-1072.	5.5	711
16	CRISPR-mediated direct mutation of cancer genes in the mouse liver. Nature, 2014, 514, 380-384.	13.7	673
17	Role for the p53 homologue p73 in E2F-1-induced apoptosis. Nature, 2000, 407, 645-648.	13.7	656
18	p53-dependent apoptosis produced by Rb-deficiency in the developing mouse lens. Nature, 1994, 371, 72-74.	13.7	625

#	Article	IF	CITATIONS
19	Environment Impacts the Metabolic Dependencies of Ras-Driven Non-Small Cell Lung Cancer. Cell Metabolism, 2016, 23, 517-528.	7.2	616
20	KRAS and YAP1 Converge to Regulate EMT and Tumor Survival. Cell, 2014, 158, 171-184.	13.5	608
21	Commensal Microbiota Promote Lung Cancer Development via γδT Cells. Cell, 2019, 176, 998-1013.e16.	13.5	592
22	MHC-II neoantigens shape tumour immunity and response to immunotherapy. Nature, 2019, 574, 696-701.	13.7	563
23	Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells. Nature Genetics, 1996, 12, 144-148.	9.4	555
24	A subset of p53-deficient embryos exhibit exencephaly. Nature Genetics, 1995, 10, 175-180.	9.4	544
25	The Differential Effects of Mutant p53 Alleles on Advanced Murine Lung Cancer. Cancer Research, 2005, 65, 10280-10288.	0.4	488
26	Expression of tumour-specific antigens underlies cancer immunoediting. Nature, 2012, 482, 405-409.	13.7	478
27	Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis. Nature Medicine, 2017, 23, 1362-1368.	15.2	462
28	Autophagy Is Required for Glucose Homeostasis and Lung Tumor Maintenance. Cancer Discovery, 2014, 4, 914-927.	7.7	450
29	Tissue of origin dictates branched-chain amino acid metabolism in mutant <i>Kras</i> -driven cancers. Science, 2016, 353, 1161-1165.	6.0	447
30	Mouse Models of Tumor Development in Neurofibromatosis Type 1 . Science, 1999, 286, 2172-2176.	6.0	441
31	LincRNA-p21 Activates p21 In cis to Promote Polycomb Target Gene Expression and to Enforce the G1/S Checkpoint. Molecular Cell, 2014, 54, 777-790.	4.5	412
32	An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis. Nature Genetics, 2005, 37, 48-55.	9.4	392
33	<scp>PKM</scp> 2, cancer metabolism, and the road ahead. EMBO Reports, 2016, 17, 1721-1730.	2.0	384
34	Suppression of lung adenocarcinoma progression by Nkx2-1. Nature, 2011, 473, 101-104.	13.7	383
35	Cooperative tumorigenic effects of germline mutations in Rb and p53. Nature Genetics, 1994, 7, 480-484.	9.4	379
36	Nf1;Trp53 mutant mice develop glioblastoma with evidence of strain-specific effects. Nature Genetics, 2000, 26, 109-113.	9.4	379

#	Article	IF	CITATIONS
37	Circadian Rhythm Disruption Promotes Lung Tumorigenesis. Cell Metabolism, 2016, 24, 324-331.	7.2	366
38	The retinoblastoma gene family in differentiation and development. Oncogene, 1999, 18, 7873-7882.	2.6	362
39	Regulatory T Cells in Tumor-Associated Tertiary Lymphoid Structures Suppress Anti-tumor T Cell Responses. Immunity, 2015, 43, 579-590.	6.6	360
40	Vascular system defects and neuronal apoptosis in mice lacking Ras GTPase-activating protein. Nature, 1995, 377, 695-701.	13.7	357
41	Rapid modelling of cooperating genetic events in cancer through somatic genome editing. Nature, 2014, 516, 428-431.	13.7	353
42	Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma. Nature Medicine, 2015, 21, 1163-1171.	15.2	349
43	Applications of the CRISPR–Cas9 system in cancer biology. Nature Reviews Cancer, 2015, 15, 387-393.	12.8	340
44	A mouse model for the learning and memory deficits associated with neurofibromatosis type I. Nature Genetics, 1997, 15, 281-284.	9.4	336
45	An intact HDM2 RING-finger domain is required for nuclear exclusion of p53. Nature Cell Biology, 2000, 2, 563-568.	4.6	312
46	Anatomically and Functionally Distinct Lung Mesenchymal Populations Marked by Lgr5 and Lgr6. Cell, 2017, 170, 1149-1163.e12.	13.5	304
47	Wildtype Kras2 can inhibit lung carcinogenesis in mice. Nature Genetics, 2001, 29, 25-33.	9.4	284
48	Cell-cycle control and its watchman. Nature, 1996, 381, 643-644.	13.7	278
49	Loss of E2F-1 reduces tumorigenesis and extends the lifespan of Rb1(+/ $\hat{a}$ -') mice. Nature Genetics, 1998, 18, 360-364.	9.4	274
50	A spatially and temporally restricted mouse model of soft tissue sarcoma. Nature Medicine, 2007, 13, 992-997.	15.2	274
51	A Wnt-producing niche drives proliferative potential and progression in lung adenocarcinoma. Nature, 2017, 545, 355-359.	13.7	265
52	A dominant-negative effect drives selection of <i>TP53</i> missense mutations in myeloid malignancies. Science, 2019, 365, 599-604.	6.0	265
53	Stage-specific sensitivity to p53 restoration during lung cancer progression. Nature, 2010, 468, 572-575.	13.7	255
54	In vivo genome editing and organoid transplantation models of colorectal cancer and metastasis. Nature Biotechnology, 2017, 35, 569-576.	9.4	248

#	Article	IF	CITATIONS
55	Genetic and Clonal Dissection of Murine Small Cell Lung Carcinoma Progression by Genome Sequencing. Cell, 2014, 156, 1298-1311.	13.5	241
56	Small RNA combination therapy for lung cancer. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E3553-61.	<b>3.</b> 3	210
57	Emergence of a High-Plasticity Cell State during Lung Cancer Evolution. Cancer Cell, 2020, 38, 229-246.e13.	7.7	210
58	Endogenous T Cell Responses to Antigens Expressed in Lung Adenocarcinomas Delay Malignant Tumor Progression. Cancer Cell, 2011, 19, 72-85.	7.7	209
59	Lung Adenocarcinoma Distally Rewires Hepatic Circadian Homeostasis. Cell, 2016, 165, 896-909.	13.5	195
60	Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 2948-2953.	<b>3.</b> 3	176
61	Notum produced by Paneth cells attenuates regeneration of aged intestinal epithelium. Nature, 2019, 571, 398-402.	13.7	166
62	Mutational landscape of <i>EGFR-</i> , <i>MYC-</i> , and <i>Kras-</i> driven genetically engineered mouse models of lung adenocarcinoma. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E6409-E6417.	<b>3.</b> 3	158
63	p21 Is a Critical CDK2 Regulator Essential for Proliferation Control in Rb-deficient Cells. Journal of Cell Biology, 1998, 141, 503-514.	2.3	145
64	Nuclear factor I/B is an oncogene in small cell lung cancer. Genes and Development, 2011, 25, 1470-1475.	2.7	142
65	Epigenomic State Transitions Characterize Tumor Progression in Mouse Lung Adenocarcinoma. Cancer Cell, 2020, 38, 212-228.e13.	7.7	140
66	Survival of pancreatic cancer cells lacking KRAS function. Nature Communications, 2017, 8, 1090.	5 <b>.</b> 8	131
67	Germline loss of PKM2 promotes metabolic distress and hepatocellular carcinoma. Genes and Development, 2016, 30, 1020-1033.	2.7	122
68	Stromal Expression of miR-143/145 Promotes Neoangiogenesis in Lung Cancer Development. Cancer Discovery, 2016, 6, 188-201.	7.7	122
69	The CD155/TIGIT axis promotes and maintains immune evasion in neoantigen-expressing pancreatic cancer. Cancer Cell, 2021, 39, 1342-1360.e14.	7.7	119
70	Spatial genomics enables multi-modal study of clonal heterogeneity in tissues. Nature, 2022, 601, 85-91.	13.7	117
71	Insights into cancer from transgenic mouse models. , 1999, 187, 43-60.		113
72	Conventional type I dendritic cells maintain a reservoir of proliferative tumor-antigen specific TCF-1+ CD8+ TÂcells in tumor-draining lymph nodes. Immunity, 2021, 54, 2338-2353.e6.	6.6	111

#	Article	IF	Citations
73	Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E1288-96.	3.3	110
74	Lineage tracing reveals the phylodynamics, plasticity, and paths of tumor evolution. Cell, 2022, 185, 1905-1923.e25.	13.5	108
75	TUMOR SUPPRESSOR GENE MUTATIONS IN MICE. Annual Review of Genetics, 1996, 30, 603-636.	3.2	104
76	Identification of DHODH as a therapeutic target in small cell lung cancer. Science Translational Medicine, 2019, $11$ , .	5.8	89
77	Foxa2 and Cdx2 cooperate with Nkx2-1 to inhibit lung adenocarcinoma metastasis. Genes and Development, 2015, 29, 1850-1862.	2.7	87
78	Antigen dominance hierarchies shape TCF1+ progenitor CD8 TÂcell phenotypes in tumors. Cell, 2021, 184, 4996-5014.e26.	13.5	84
79	In Vitro and In Vivo Effects of a Farnesyltransferase Inhibitor onNf1-Deficient Hematopoietic Cells. Blood, 1999, 94, 2469-2476.	0.6	81
80	Endocrine-Exocrine Signaling Drives Obesity-Associated Pancreatic Ductal Adenocarcinoma. Cell, 2020, 181, 832-847.e18.	13.5	77
81	Colonoscopy-based colorectal cancer modeling in mice with CRISPR–Cas9 genome editing and organoid transplantation. Nature Protocols, 2018, 13, 217-234.	5.5	74
82	Radiation-induced neoantigens broaden the immunotherapeutic window of cancers with low mutational loads. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	62
83	Dissecting cell-type-specific metabolism in pancreatic ductal adenocarcinoma. ELife, 2020, 9, .	2.8	61
84	Urinary detection of lung cancer in mice via noninvasive pulmonary protease profiling. Science Translational Medicine, 2020, 12, .	5.8	58
85	Low neoantigen expression and poor T-cell priming underlie early immune escape in colorectal cancer. Nature Cancer, 2021, 2, 1071-1085.	5.7	57
86	Myeloid Malignancies Induced by Alkylating Agents in Nf1 Mice. Blood, 1999, 93, 3617-3623.	0.6	55
87	A Modular Assembly Platform for Rapid Generation of DNA Constructs. Scientific Reports, 2016, 6, 16836.	1.6	54
88	IL-33 Signaling Alters Regulatory T Cell Diversity in Support of Tumor Development. Cell Reports, 2019, 29, 2998-3008.e8.	2.9	53
89	Optofluidic real-time cell sorter for longitudinal CTC studies in mouse models of cancer. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 2232-2236.	3.3	51
90	Regulated Expression of a Tumor-Associated Antigen Reveals Multiple Levels of T-Cell Tolerance in a Mouse Model of Lung Cancer. Cancer Research, 2008, 68, 9459-9468.	0.4	45

#	Article	IF	CITATIONS
91	Keap1 mutation renders lung adenocarcinomas dependent on Slc33a1. Nature Cancer, 2020, 1, 589-602.	5.7	44
92	The CCL2-CCR2 astrocyte-cancer cell axis in tumor extravasation at the brain. Science Advances, 2021, 7, .	4.7	40
93	Deciphering the immunopeptidome in vivo reveals new tumour antigens. Nature, 2022, 607, 149-155.	13.7	38
94	Rebalancing Protein Homeostasis Enhances Tumor Antigen Presentation. Clinical Cancer Research, 2019, 25, 6392-6405.	3.2	37
95	Therapeutic avenues for cancer neuroscience: translational frontiers and clinical opportunities. Lancet Oncology, The, 2022, 23, e62-e74.	5.1	36
96	Lessons from thep53 mutant mouse. Journal of Cancer Research and Clinical Oncology, 1996, 122, 319-327.	1.2	33
97	Inducible de novo expression of neoantigens in tumor cells and mice. Nature Biotechnology, 2021, 39, 64-73.	9.4	32
98	Live cell tagging tracking and isolation for spatial transcriptomics using photoactivatable cell dyes. Nature Communications, 2021, 12, 4995.	5.8	25
99	Isoform-specific deletion of PKM2 constrains tumor initiation in a mouse model of soft tissue sarcoma. Cancer & Metabolism, 2018, 6, 6.	2.4	24
100	<i>Rlf–Mycl</i> Gene Fusion Drives Tumorigenesis and Metastasis in a Mouse Model of Small Cell Lung Cancer. Cancer Discovery, 2021, 11, 3214-3229.	7.7	24
101	Mitochondrial apoptotic priming is a key determinant of cell fate upon p53 restoration. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	20
102	Measuring kinetics and metastatic propensity of CTCs by blood exchange between mice. Nature Communications, 2021, 12, 5680.	5.8	18
103	Deletion of p21 cannot substitute for p53 loss in rescue of mdm2 null lethality. Nature Genetics, 1997, 16, 336-337.	9.4	16
104	Dicer loss and recovery induce an oncogenic switch driven by transcriptional activation of the oncofetal Imp1â€"3 family. Genes and Development, 2017, 31, 674-687.	2.7	16
105	Pan-cancer Transcriptomic Predictors of Perineural Invasion Improve Occult Histopathologic Detection. Clinical Cancer Research, 2021, 27, 2807-2815.	3.2	12
106	p53 and treatment of bladder cancer. Nature, 1997, 385, 124-125.	13.7	10
107	A bumper crop of cancer genes. Nature Genetics, 1999, 23, 253-254.	9.4	9
108	A Conditional System to Specifically Link Disruption of Protein-Coding Function with Reporter Expression in Mice. Cell Reports, 2014, 7, 2078-2086.	2.9	9

#	Article	IF	CITATIONS
109	Protocol for single-cell ATAC sequencing using combinatorial indexing in mouse lung adenocarcinoma. STAR Protocols, 2021, 2, 100583.	0.5	9
110	A GATA4-regulated secretory program suppresses tumors through recruitment of cytotoxic CD8 T cells. Nature Communications, 2022, 13, 256.	5.8	8
111	Coordinate Loss of a MicroRNA Mir 145 and a Protein-Coding Gene RPS14 Cooperate in the Pathogenesis of 5q- Syndrome Blood, 2009, 114, 947-947.	0.6	7
112	Driving Rel-iant Tregs toward an Identity Crisis. Immunity, 2017, 47, 391-393.	6.6	5
113	The Role of K-ras Signaling in Erythropoiesis In Vivo Blood, 2005, 106, 3136-3136.	0.6	O
114	Anti-Tumor TCF1+ CD8 T Cells are Functionally Diverse and Evolve During Tumorigenesis and Progression. American Journal of Clinical Pathology, 2020, 154, S5-S6.	0.4	0